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Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle
progenitors, preserving the expression of genes critical for embryonic myogenic development such as MYOD1 and myogenin.
RMS is classiﬁed as embryonal, which is more common in younger children, or alveolar, which is more prevalent in elder
children and adults. Despite aggressive management including surgery, radiation, and chemotherapy, the outcome for children
with metastatic RMS is dismal, and the prognosis has remained unchanged for decades. Apoptosis is a highly regulated process
critical for embryonic development and tissue and organ homeostasis. Like other types of cancers, RMS develops by evading
intrinsicapoptosisviamutationsinthep53tumorsuppressorgene.However,theabilitytoinduceapoptosisviathedeathreceptor-
dependent extrinsic pathway remains largely intact in tumors with p53 mutations. This paper focuses on activating extrinsic
apoptosis as a therapeutic strategy for RMS by targeting the death receptor DR5 with a recombinant TRAIL ligand or agonistic
antibodies directed against DR5.
1.Introduction
Rhabdomyosarcoma (RMS) is the most common pediatric
soft-tissue tumor. Despite extensive research and aggressive
clinical management, the overall outcome for children
with metastatic disease is dismal with a prognosis largely
unchanged in decades [1, 2]. RMS tumors are histologically
classiﬁed into two major subtypes, embryonic (ERMS) and
alveolar (ARMS), which are associated with unique genetic
changes. The majority of ARMSs are characterized by the
presence of PAX3/7:FOXO1 translocation [3, 4]. ERMSs, on
theother hand, aremorefrequentlyassociated withactivated
RAS signaling via mutations in RAS genes or deletions in
NF1, a tumor suppressor that encodes an RAS inhibitor
[5–7].
The two subtypes of RMS also have distinct prognoses.
ERMSs are often found in younger patients who generally
do better, whereas ARMSs are more frequently diagnosed in
adolescents and young adults who have a worse prognosis
with a ﬁve-year survival rate of less than 50% [8–11].
Additional mutations in tumor suppressors are important
for the development of RMS. In particular, RMS is the most
common pediatric cancer in families with Li-Fraumeni syn-
drome[12].Mutationsinp53areimportantforpathogenesis
and commonly found in RMS [13, 14].
Despite advances in radiation and chemotherapy, there
has been little change in the 5-year survival rate for pediatric
RMS [10] .T h ec u r er a t ef o ra d v a n c e dR M Si sn o te x p e c t e d
to improve signiﬁcantly until eﬀective targeted and tumor-
speciﬁc agents are developed. Recent advances in targeted
therapies provide fresh alternatives for therapeutic develop-
ment against RMS. Many new and novel agents targeting
receptor tyrosine kinases are in various stages of clinical
development that may beneﬁt RMS patients, including those
targeting PDGFR, EGFR, VEGFR1-3, SRC, and IGF1R [15].
Unfortunately, the inhibition of a single receptor tyrosine2 ISRN Oncology
kinase only has modest activity in some cases. Additional
targeted agents are clearly needed to have better control of
the disease.
Apoptosis or programmed cell death is a naturally
occurring process for removing unwanted cells in the body.
Impaired apoptosis plays a key role in cancer pathogenesis
through uncontrolled cell growth and contributes to poor
chemotherapy responses. Apoptosis can be achieved by
the activation of the intrinsic, mitochondria-dependent
pathway or the extrinsic, death receptor-mediated pathway.
The frequent inactivation of p53 enables cancer cells not
only to bypass the intrinsic apoptotic response to their
genomic aberrations, but also to escape apoptosis induced
by various conventional DNA-damage therapeutic agents
[16]. Therefore, targeting the extrinsic, death receptor-
mediated pathway provides a new alternative to current
cancer therapies [17].
TNF-related apoptosis-inducing ligand (TRAIL) is a
membrane of the TNF family of cytokines [18]. Binding
of TRAIL to death receptors DR4 (TRAIL-R1) and/or DR5
(TRAIL-R2) results in the assembly of the death-induced
signaling complex (DISC) involving the FAS-associated
death domain (FADD) protein and caspase-8 or -10 [19,
20]. Due to the selectivity of TRAIL towards cancer cells,
there has been a signiﬁcant interest in developing agents
targeting TRAIL receptors for the treatment of various
cancers [17, 21]. Some of them, including the recombinant
TRAIL ligand as well as agonistic therapeutic antibodies
directed against DR4 and DR5, are currently under clinical
development. In this paper, we will discuss the therapeutic
potentials of agents targeting the death receptor DR5 for
RMS.
2.Inducing Extrinsic Cell Death in Tumors via
DeathReceptorActivation
A main mechanism for cell death, apoptosis is a natural
cellular suicide program aimed to eliminate those cells that
are no longer in need or that have sustained severe damage
to their DNA [22]. Apoptosis has critical roles in embry-
onic development and tissue homeostasis. Deregulation of
apoptosis is crucial for the development of cancer [23, 24].
The inactivation of the tumor suppressor p53 enables cancer
cells to bypass programed cell death in response to DNA
mutations and chromosome aberrations [16]. Apoptosis
occurs primarily via intrinsic and extrinsic pathways that are
generally separate but sometimes intersect (Figure 1).
2.1. The Intrinsic Apoptosis Pathway. The intrinsic pathway
is activated by the loss of growth factor signals or by severe
cellular stress such as DNA damage and is controlled by
members of the Bcl-2 protein family [25, 26]. Activation
of proapoptotic family members BAX and BAK results in
the permeabilization of mitochondrial membranes, releasing
cytochromeCandSmac/DIABLOintothecytoplasm(Figure
1)[ 27]. The released cytochrome C facilitates the formation
of the apoptosome, consisting of Apaf-1, cytochrome C, and
procaspase-9. The subsequent activation of caspase-9 leads
to the cleavage of downstream eﬀector caspases-3, -6 and
-7 [28]. Smac/DIABLO enhances apoptosis by interacting
with and blocking the activities of the inhibitors of apoptosis
proteins (IAPs) [29].
Thispathwayisparticularlyimportantforcancertherapy
since both chemo- and radiation therapies result in DNA
damage and the activation of the p53 checkpoint [30].
p53 is a master regulator of apoptosis that responds to a
variety of cellular stresses, including DNA damage, hypoxia,
and nutrient deprivation [31, 32]. It promotes apoptosis by
inducing the expression of proapoptotic genes, including
PUMA, NOXA, BID, BAX,a n dAPAF-1 [33]. Various studies
have shown that inactivation of BAX or PUMA, or the
overexpression of BCL-2 or BCL-xL,c a ne ﬀectively promote
tumorigenesis, suggesting that p53-mediated apoptosis is a
signiﬁcant contributor to tumor development [33].
Notably, RMS is the most common cancer in pediatric
patients carrying germline p53 mutations [34], and mutated
p53 is frequently found in RMS [13, 35]. p53 was shown
to mediate radiation and anticancer agent-induced cellular
apoptosis [36, 37]. Similarly, p53 is important for conferring
cellular sensitivity to chemotherapeutic agents in RMS [38].
Thus, there is a need to explore agents targeting RMS
independent of p53 mutation status.
2.2. The Extrinsic Apoptosis Pathway. The extrinsic pathway
is activated by proapoptotic receptors on the cell surface.
The biological process of the extrinsic apoptosis pathway has
been extensively investigated. The binding of TRAIL to the
death receptors DR4 and/or DR5 causes the trimerization
of the receptors and the recruitment of the FADD protein
[19].
Subsequently, FADD attracts initiator caspase-8 or -10
through its death eﬀector domain to form the death-
inducing signal complex (DISC), in which the initiator
caspases are activated by proteolysis (Figure 1). Activated
caspase-8 or -10 then cleaves the eﬀector caspase-3, which in
turn leads to the cleavage of death substrates. The activation
of caspase-8 can be regulated by FLICE-like inhibitor protein
c-FLIP [39] and by caspase-8 ubiquitination [40].
There are two types of intracellular signaling linked to
the extrinsic apoptosis pathway [50, 51]. In type I signaling,
caspase-8 activation is suﬃc i e n tt oc o m m i tac e l lt oa p o p t o -
sis. The activated caspase-8 or -10 then cleaves downstream
eﬀector caspase-3, which in turn results in the cleavage
of death substrates. In type II apoptotic signaling, further
signal ampliﬁcation is needed and is achieved through
caspase-8-mediated cleavage of Bid. Bid then participates in
the mitochondrial-dependent intrinsic pathway to enhance
apoptotic activity.
2.3. TRAIL Receptors as Therapeutic Targets. Proapoptotic
receptors are potentially attractive targets for cancer therapy
because they are widely expressed in tumors. In addition,
common oncogenes including Myc and Ras, which are
often activated in RMS [5, 52, 53], appear to increase
tumor sensitivity to the extrinsic pathway [54–56]. More
importantly,theextrinsicpathwaycanbeeﬀectivelyactivatedISRN Oncology 3
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Figure 1: Diagram of intrinsic and extrinsic apoptosis.
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function is common in RMS and leads to resistance to
traditional chemo- and radiation therapies.
Three ligands belong to the tumor-necrosis factor (TNF)
superfamily, TNFα, FAS ligand, and TRAIL. The proinﬂam-
matory eﬀects of TNFα have signiﬁcantly limited its clinical
development [57]. Agonistic antibodies to FAS or FAS ligand
were considered unsuitable for clinical development as they
cause massive hepatocyte apoptosis and lethal liver damage
in animal models [58, 59]. Agents targeting TRAIL receptors
DR4 and DR5 were shown to be well tolerated in both
preclinical models and phase I clinical trials [41, 46, 60].
Thus, TRAIL death receptors are considered feasible targets
for the development of antitumor agents.
Much eﬀort has been made to understand tumor sensi-
tivityandresistancetoTRAIL-inducedapoptosis.Priorstud-
ies showed that DR4 and DR5 receptor levels are not well
correlatedwithsensitivitytoapoptosisstimulation.Extensive
research was carried out to identify tumor biomarkers pre-
dictive of sensitivity or resistance to agents targeting TRAIL
receptors. Multiple factors have been suggested to aﬀect
TRAIL-induced apoptosis. Decoy receptors DcR1, DcR2,
and OPG can bind to TRAIL without mediating death
signaling, thereby competing for available TRAIL [61]. The
posttranslational O-glycosylation [62]a n de n d o c y t o s i s[ 63]
of DR4 and DR5 were implicated as mechanisms aﬀecting
TRAIL-induced cell death. Reduced expression of caspase-8
via epigenetic silencing [64, 65] or increased ubiquitination
of caspase-8 protein [40] also limits TRAIL signaling. c-
FLIP functions as an important inhibitor for TRAIL-induced
apoptosis, by competing with the recruitment of caspases-
8 and -10 to the DISC [66]. In tumor cells with type II
TRAIL-induced apoptosis, cell death can be blocked by the
overexpression of antiapoptotic Bcl-2 proteins, such as Bcl-
2 and Bcl-xL [17]. Downstream caspase activity can be
further inhibited by XIAP [67] and cIAP [68]. Conversely,
inhibition of the PI3K/AKT pathway sensitizes tumor cells
to TRAIL treatment and reverses TRAIL resistance [69].
These important studies may facilitate the identiﬁcation
and implementation of predictive biomarkers for the clin-
ical development of TRAIL-based therapeutics for can-
cer.4 ISRN Oncology
3.TargetingDeathReceptors
inRhabdomyosarcoma
3.1. Selectivity of TRAIL and DR5 Antibodies to Rhab-
domyosarcoma. Amongst various sarcomas, many RMS and
Ewing’s sarcoma (EWS) cell lines are sensitive to single-agent
TRAIL [70–76]. Nearly half of the RMS cell lines examined
have a sensitivity comparable to that of the most sensitive
breast cancer cell line MDA-MB-231 [70, 76]. The activity
of TRAIL appears to be speciﬁcally mediated through death
receptor DR5 in these RMS cell lines, because only DR5,
not DR4, is expressed [76]. This result is further supported
by the observation that those RMS cell lines sensitive to
TRAIL are also sensitive to antibodies against DR5 but are
completely resistant to those directed toward DR4 [76].
Similarly, the majority of Ewing’s sarcomas are also sensitive
to TRAIL [73]. DR5 receptor also appears to have a greater
roleinmediatingtheproapoptoticactivityofTRAILinEWS.
Though both DR4 and DR5 are expressed by EWS cell lines,
onlyDR5isdetectedonthecellsurface[75].Thus,bothRMS
and EWS can be eﬀectively induced to undergo apoptosis via
the DR5 receptor.
3.2. Biomarkers Predictive of TRAIL Sensitivity. Although
DR5 is the direct target of TRAIL ligand or its agonistic
antibodies in RMS cells, it is expressed by all cells, regardless
of their sensitivity to TRAIL or DR5 antibodies. The analysis
of the expression of decoy receptors DcR1 and DcR2 did
not show a correlation with TRAIL sensitivity in either RMS
or EWS [70, 75]. In contrast, investigations revealed a good
correlation between the expression of caspase-8 and TRAIL
sensitivity in RMS [70, 76]. The level of caspase-8 is clearly
important for DR5-mediated apoptosis. In cells with very
low caspase-8, the DR5 antibody drozitumab fails to induce
the assembly of DISC or the subsequent activation of cas-
pases necessary for apoptosis. More importantly, the expres-
sion of wild type, but not catalytically inactive, CASP8 con-
fers drozitumab sensitivity to resistant RMS cells, indicating
that expression of active caspase-8 is a predictive biomarker
forRMSsensitivitytoDR5-targetedagents[76].Thepreclin-
ical analysis of cellular components critical for RMS sensi-
tivity to DR5-targeted agents suggests that caspase-8 should
serveasbiomarkerforsubsequentclinicalcorrelativestudies.
Caspase-8 is a protein crucial for death receptor-
mediated apoptosis. Mutations in CASP8 were detected in
colorectal, liver, and gastric cancer [77–79]. Inactivating
mutations were also detected in head and neck tumors [80].
In addition, genomic deletions or silencing of CASP8 are
frequent in neuroblastoma with MYC ampliﬁcation [81].
While deletion of CASP8 is common in neuroblastoma
resulting in reduced expression and sensitivity to TRAIL
[65, 82, 83], these genomic changes are not common in
RMS or EWS [84]. CASP8 expression appears to be regulated
by hypermethylation, and agents that alter methylation
status can lead to increased sensitivity to TRAIL and death
receptor activation [83, 85]. It was suggested that the
addition of DNA methyltransferase inhibitors, such as 5-
dAzaC, may restore CASP8 expression and sensitize resistant
cells to TRAIL-induced apoptosis in some neuroblastoma
and medulloblastoma cells [85]. It is not known whether
agents targeting DNA methyltransferase could induce the
expression of CASP8 in RMS.
3.3. Agents Sensitizing Rhabdomyosarcoma and Ewing’s Sar-
coma to Death-Receptor-Targeted Agents. Like many other
targetedagents,thecombinationofTRAIL-receptor-targeted
agents with numerous conventional and investigational
anticancer agents has been tested in many preclinical models
[21]. The agents used in combination studies include a wide
varietyoftraditionalchemotherapeuticagentsandradiation,
proteasome inhibitors, histone deacetylase inhibitors, and
various investigational inhibitors of Bcl-2 and IAP [21]. In
EWS cells, the combination of TRAIL with a proteasome
inhibitor, a DNA demethylating agent, or interferon γ
showed initial promise [75, 83, 86]. Combination stud-
ies with TRAIL were also performed against RMS cells.
In one instance, the chemotherapeutic agent doxorubicin
potentiated TRAIL cytotoxicity in resistant RMS cells [87].
Interestingly, other studies revealed that both casein kinases
I and II appear to inhibit TRAIL-induced apoptosis in
RMSs and shRNA-mediated gene silencing of either kinase
increases the sensitivity of RMS to TRAIL [88, 89].
3.4. Preclinical In Vivo Results with Death-Receptor-Targeted
Agents to Combat Rhabdomyosarcoma and Ewing’s Sarcoma.
Preclinical in vivo testing against EWS was performed using
lipid-based gene transfer into nude mice inoculated with
a sensitive EWS cell line. TRAIL transgene was shown to
decrease tumor progression and increase animal survival
[71]. Although this gene transfer method is not likely to be
implemented in clinical trials, the results suggest that TRAIL
can be a promising candidate for therapeutic development.
The preclinical investigation of a therapeutic agent against
RMS was performed with the DR5 agonistic antibody
drozitumab in an SCID mouse xenograft model. The results
showed that weekly injection of drozitumab had potent
antitumor activity against RMS tumors that was associated
with rapid tumor regression and durable response. Further,
drozitumab has the selectivity against RMS cells predicted
from the in vitro cell-based studies [76], thus, providing the
preclinical validation of a DR5-targeted agent for followup
clinical investigations in patients with RMS.
4. ClinicalDevelopment of Therapeutics
TargetingDeathReceptors
There are currently two approaches in targeting death recep-
tors: recombinant human (rh) TRAIL protein that activates
bothDR4andDR5andagonisticmonoclonalantibodiesthat
activate either DR4 or DR5 [21]. Recently, both rhTRAIL
and agonistic antibodies have entered clinical trials as either
single agents or in combination with chemotherapeutic or
other targeted agents.
4.1. Recombinant Human TRAIL. In a phase I trial in
patients with solid tumors or hematological malignancies,
rhTRAIL, or dulanermin, was well tolerated [41]. Overall,ISRN Oncology 5
46% of patients had stable disease, and two patients with
chondrosarcoma had a partial response [41]. One of the
potential limitations for dulanermin was its very short half-
life between 30min and 1 hour. Thus, the drug is only at or
aboveeﬀectivelevelsverybrieﬂyduringthe5-dayinfusionof
each treatment cycle.
Dulanermin was also evaluated in combination with
a number of chemo- and other targeted therapies. In
metastatic colorectal cancer, dulanermin was evaluated
together with irinotecan and cetuximab or FOLFIRI. The
initial results suggest that they can be combined safely [90].
Dulanerminincombinationwithpaclitaxel,carboplatin,and
bevacizumab has also been evaluated in 24 patients with
previously untreated non-small-cell lung cancer (NSCLC)
[49]. The combination is safe, and thirteen partial responses
and one complete response were reported in this study. The
response rate (58%) was considered higher than that in a
previous study in advanced NSCLC without the addition
of dulanermin (35%). Dulanermin was also evaluated in
combination with rituximab in patients with low grade
non-Hodgkin lymphoma (NHL) that had relapsed following
previous rituximab-containing therapy. Initial results of the
ﬁve subjects available for analysis revealed that two had a
complete response, one had a partial response, and two had
stable disease [91]. A larger phase II study comparing ritux-
imab with or without dulanermin in patients with relapsed
follicular NHL is in progress. Currently, there is no informa-
tion or ongoing trials of dulanermin in RMS patients.
As a recombinant TRAIL ligand, dulanermin has a num-
ber of unique properties when compared to the agonistic
antibodies. It possesses a much shorter serum half-life of 30–
60min [41], less than 1% of that for an agonistic antibody.
Thus, dulanermin requires more frequent dosing to achieve
a durable antitumor response. In practice, the plasma
dulanermin concentration is below the desired level for most
of the time during a treatment cycle. Also, dulanermin binds
both DR4 and DR5 and could theoretically have a broader
activity proﬁle or greater toxicity over agents that are speciﬁc
for either receptor. It is not clear whether binding to decoy
receptors could aﬀect the drug’s activity. In addition, unlike
manyDR4or DR5targeted agonistic antibodies, dulanermin
does not require exogenous cross-linking or Fcγ receptor
(FcγR) interactions for its activity in preclinical studies [92].
DuetothelackofcorrelationbetweenthelevelsofTRAIL
receptors in tumor cell lines and their drug sensitivities,
alternate biomarkers of tumor cell sensitivity are required
[93]. Elevated expression of O-glycosylation-initiating and
-processing enzymes was correlated with TRAIL sensitivity
in various tumor cell lines [62]. Furthermore, DR4 and DR5
were shown to be targets of O-glycosylation that facilitated
ligand-induced receptor clustering and caspase activation,
suggesting that O-glycosylating enzymes and their targets
may be predictive biomarkers of response to the treatment
with dulanermin [94].
4.2. Agonistic Antibody against DR5. As described earlier,
RMS cell lines have neither expression of DR4 nor sensitivity
to a DR4 antibody [76]. Thus, only agonistic antibodies
against DR5 are likely to be eﬀective. Multiple phase I single
agent studies with advanced tumors were completed with
lexatumumab [42–44], drozitumab [45], conatumumab [46,
47], and TRA-8/CS-1008 [48]( Table 1). These agonistic
antibodies were generally well tolerated at the doses tested,
and most did not reach the maximum tolerated dose.
These antibodies have a half-life of 1–3 weeks, much longer
than that of dulanermin. The antibodies are administered
biweekly, far less frequently than the daily dosing with
dulanermin. Moreover, due to their long half-lives, the
steady-state levels of these antibodies can stay above the
eﬀective dose throughout the duration of the treatment,
instead of an hour or so during the time of infusion with
dulanermin.
Despite multiple reports of stable disease with DR5-
targeted agonistic antibodies, of the single-agent trials, only
conatumumab was shown to have modest activity at phase
I with a partial response in a patient with NSCLC [46]. The
initial clinical studies with DR5-targeted antibodies indicate
rather low initial clinical activities. Additional work such as
antibodyoptimization,patientstratiﬁcationbasedoncertain
biomarkers, or combination with other agents to synergize
the activity of the antibody may be required to achieve better
clinical outcomes.
Various agonistic human DR4 and DR5 antibodies
display maximal proapoptotic activity in in vitro assays
upon artiﬁcial Fc antibody or protein G cross-linking. In
the absence of the cross-linking, most DR5 therapeutic
antibodies exhibited low to minimal activity in vitro against
target tumor cells [95–98]. In vivo, their activity requires
interaction with the FcγR that is present on leukocytes
[92]. Polymorphisms in human FcγRa ﬀect both antibody
binding and the antibody’s pro-apoptotic activity against
tumor cells [92]. Also, the proximity between target cells and
leukocytes expressing FcγR in solid tumors may constrain
the accessibility of the tumors to the cross-linked agonistic
antibodies. Our recent results showed that a mouse mono-
clonal antibody can eﬀectively kill target tumor cells without
cross-linking,withapotencycomparabletothatofthecross-
linkeddrozitumab[76].Thus,additionaloptimizationofthe
agonistic antibodies may be required for optimal antitumor
activity that is either independent of cross-linking or less
subject to the eﬀects of polymorphisms in the human FcγR.
Combining the death receptor antibodies with stan-
dard chemotherapy or targeted agents may enhance their
antitumor activities through the crosstalk between the
extrinsic and intrinsic apoptotic pathways. Several clini-
cal safety studies of DR5 agonists in combination with
chemotherapy and/or targeted agents are in progress in
advanced solid tumors (Table 1). DR5 agonistic antibodies
can be safely combined with standard doses of cancer
therapeutics in small cohorts of patients. The combina-
tions did not lead to signiﬁcant drug-to-drug interactions
or to signiﬁcantly sensitize normal cells to apoptosis.
These combinations include single cytotoxic agents (dox-
orubicin, gemcitabine, and pemetrexed), cytotoxic agent
combinations (carboplatin/paclitaxel, cisplatin/gemcitabine,
and FOLFIRI), targeted agents (bortezomib, panitumumab,
rituximab, and vorinostat), and cytotoxic-targeted agent6 ISRN Oncology
Table 1: Death receptor-targeted agents in clinical development.
Agents Phase Target Cancer Current status Responses Ref.
Dulanermin 1 Advanced Ca Completed 2 PR Chondrosarcoma, 46% SD [41]
Lexatumumab 1 Advanced Ca Completed No PR, 32% SD [42]
Lexatumumab 1 Advanced Ca Completed No PR, 29% SD [43]
Lexatumumab 1 Advanced Ca Completed 21% SD [44]
Drozitumab 1 Advanced Ca Completed 3 minor response, 49% SD [45]
Drozitumab 2 Chondrosarcoma Terminated NA NA
Conatumumab 1 Advanced Ca Completed 1 PR NSCLC, 38% SD [46]
Conatumumab 1 Advanced Ca Completed 50% SD [47]
Tigatuzumab 1 Advanced Ca Completed 41% SD [48]
Combination
Dulanermin 1b NSCLC Completed Paclitaxel, carboplatin, and bevacizumab [49]
Dulanermin 1b Colon Ca Recruiting Camptosar/Erbitux or FOLFIRI NA
Dulanermin 1b Colon Ca Active FOLFOX, Bevacizumab NA
Dulanermin 2 NHL Completed Rituximab NA
Lexatumumab 1 Pediatric Ca Completed IFNγ NA
Drozitumab 2 NSCLC Completed Paclitaxel, carboplatin, and bevacizumab NA
Drozitumab 1b Colon Ca Completed lrinotecan, cetuximab, and FOLFIRI with
bevacizumab
NA
Drozitumab 1b Colon Ca Completed FOLFOX and Bevacizumab NA
Drozitumab 2 NHL Completed Rituximab NA
Conatumumab 1b NHL Suspended bortezomib or vorinostat NA
Conatumumab 1b/2 Colon Ca Active mFOLFOX6 and Bevacizumab NA
Conatumumab 1b/2 Advanced Ca Active Anti-IGF1R NA
Conatumumab 1b/2 NSCLC Completed Paclitaxel and carboplatin NA
Conatumumab 1b/2 Soft tissue sarcoma Active Doxorubicin NA
Conatumumab 1b/2 Pancreatic Ca Active gemcitabine NA
Conatumumab 2 Colon Ca Active FOLFIRI NA
Conatumumab 1b/2 Colon Ca Active panitumumab NA
Abbreviations: NHL, non-Hodgkin’s lymphoma, NSCLC, non-small-cell lung carcinoma, PR, partial response, and SO, stable disease.
combinations (carboplatin/paclitaxel/bevacizumab, FOL-
FOX/bevacizumab, and irinotecan/cetuximab). A number of
such studies of particular interest to RMS researchers and
patients include conatumumab (AMG655) and insulin-like
growth factor 1 receptor antibody AMG479 in advanced,
refractory solid tumors; conatumumab and doxorubicin for
the ﬁrst-line treatment of soft tissue sarcoma. Some of the
combination studies have moved to the randomized phase II
stage with results anticipated in the next two years.
5. Conclusions
Because of the potential promise of inducing programmed
cell death independent of p53 mutation status, agents
targeting TRAIL receptor DR4 and DR5 have been evaluated
in more than 20 clinical trials as single agents or in
combinations [21, 99, 100]. When administered as single
agents, they exhibited modest clinical activity with objective
responses in two chondrosarcoma patients treated with
rhTRAIL [41], and in one NSCLC patient with conatu-
mumab [46]. Until randomized studies are completed, it is
too early to tell whether the death receptor targeted agents
are active in various combinations. Both dulanermin and
agonistic antibodies have limitations that may aﬀect their
clinical eﬃcacy. Dulanermin has a half-life of less than
one hour and is expected to be eﬀective for a very short
period during the 5-day infusion treatment cycle [41]. Most
of the agonistic antibodies require cross-linking for their
activities in vitro.A n din vivo, their activities may depend
on leukocyte penetration and favorable FcγRp o l y m o r p h i s m
[92].Thus,thesetherapeuticagentstargetingdeathreceptors
may need to be further improved for stability or cross-
linking-independent activity.
As a group, RMS cells show high sensitivity to TRAIL
in vitro, where TRAIL activity is mediated through DR5
activation [70, 76]. Preclinical studies showed that the
DR5 agonistic antibody drozitumab is selective and very
eﬀective against a subgroup of RMS both in vitro and in
vivo, with caspase-8 expression predictive of response [76].
The continuous improvement of agents targeting DR5 and
patient selection may prove to be critical for the success of
this group of agents.ISRN Oncology 7
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